Prothena Corp. (PRTA) announced after the bell Thursday that its Phase 1 study of PRX002, a potential treatment of Parkinson's disease, met its primary objective. The study showed that PRX002 leads to mean reduction of free serum alpha-synuclein levels of up to 96%.
Prothena gapped open dramatically higher Friday, but gave back some of its gains around midday. The stock finished up by 9.43 at $38.66 on the highest volume of the year. Prothena soared past the upper end of a 1-month trading range and set nearly an 11-month high.
For comments and feedback contact: editorial@rttnews.com
Business News